Repros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
The information in this Current Report is being furnished to Item
7.01 of Form 8-K and, according to general instruction B.2.
thereunder, the information in this Current Report shall not be
deemed filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement to the Securities Act of 1933, as amended.
Representatives of Repros Therapeutics Inc., a Delaware
corporation (the Company) are presenting updates on the Companys
Proellex and Enclomiphene clinical programs to various investors
and other interested parties May 2 through May 3, 2017, in
Boston, MA and New York, NY, using slides containing the
information attached to this Current Report on Form 8-K as
Exhibit 99.1. These slides contain statements that are
forward-looking statements subject to the cautionary statement
about forward-looking statements set forth therein.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit | |
| Number | Description |
| 99.1 | Repros Therapeutics Slideshow |
About Repros Therapeutics Inc. (NASDAQ:RPRX)
Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids. Repros Therapeutics Inc. (NASDAQ:RPRX) Recent Trading Information
Repros Therapeutics Inc. (NASDAQ:RPRX) closed its last trading session up +0.01 at 1.02 with 86,577 shares trading hands.